Kodiak Sciences
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 111
- Market Cap
- $138.9M
- Introduction
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Clinical Trials
43
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (43 trials with phase data)• Click on a phase to view related trials
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
- Conditions
- Macular Edema Secondary to Inflammation
- Interventions
- Other: Sham Comparator
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 150
- Registration Number
- NCT06996080
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
- Conditions
- Macular Edema Secondary to Inflammation
- Interventions
- Other: Sham Comparator
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 150
- Registration Number
- NCT06990399
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 675
- Registration Number
- NCT06556368
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Retina Macula Institute of Arizona, Scottsdale, Arizona, United States
🇺🇸Retina Associates SW, Tucson, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
- Conditions
- Diabetic Retinopathy
- Interventions
- Other: Sham injection
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 255
- Registration Number
- NCT06270836
- Locations
- 🇺🇸
Retina Associates SW, Tucson, Arizona, United States
🇺🇸Retina Consultants of Orange County, Fullerton, California, United States
🇺🇸Global Research Management, Inc. - Lugene Eye Institute, Glendale, California, United States
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
- Conditions
- Non-proliferative Diabetic Retinopathy
- Interventions
- Other: Sham injection
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 253
- Registration Number
- NCT05066230
- Locations
- 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Retina Vitreous Associates, Beverly Hills, California, United States
🇺🇸Retina Consultants of Orange County, Fullerton, California, United States
- Prev
- 1
- 2
- 3
- Next